Reports Q4 revenue $100K, consensus $220K. Based upon its current operating plan and balance sheet as of December 31, 2022, Synlogic expects to have sufficient cash to be able to fund operations into the second half of 2024. "Last year was a tremendous year for Synlogic and our Synthetic Biotic platform given our three positive clinical readouts in three different diseases in the fourth quarter alone," said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer. "We are on track to initiate Synpheny-3, the pivotal Phase 3 study for SYNB1934 in PKU, our lead program, and we were thrilled to present three data presentations – including Phase 2 PKU data as a platform presentation – at the SIMD Annual Meeting."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SYBX:
- Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
- Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria
- Synlogic receives positive EMA opinion on orphan designation for SYNB1934
- Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
- Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
